Format

Send to

Choose Destination
Chest. 1998 Jan;113(1):165-71.

Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials.

Author information

1
Department of Anesthesia, Children's Hospital, Harvard Medical School, Boston, USA.

Abstract

OBJECTIVE:

To evaluate the effect of heparin on thrombus formation and infection associated with use of central venous and pulmonary artery catheters.

DATA SOURCES:

We used MEDLINE, EMBASE, citation review of relevant primary and review articles, personal files, and contact with expert informants.

STUDY SELECTION:

Fourteen randomized controlled trials evaluating prophylactic doses of heparin or heparin bonding were included.

DATA EXTRACTION:

In duplicate, independently, we abstracted data on the population, intervention, outcome, and methodologic quality.

DATA SYNTHESIS:

Prophylactic heparin decreases catheter-related venous thrombosis (relative risk [RR], 0.43; 95% confidence interval [CI], 0.23, 0.78) and bacterial colonization (RR, 0.18; 95% CI, 0.06, 0.60) of central venous catheters and may decrease catheter-related bacteremia (RR, 0.26; 95% CI, 0.07, 1.03). Heparin bonding decreases the risk of pulmonary artery catheter clot formation within 24 h (RR, 0.08; 95% CI, 0.02, 0.37).

CONCLUSIONS:

Heparin administration effectively reduces thrombus formation and may reduce catheter-related infections in patients who have central venous and pulmonary artery catheters in place. Cost-effectiveness comparisons of unfractionated heparin, low molecular weight heparin, and warfarin are needed.

Comment in

  • ACP J Club. 1998 Jul-Aug;129(1):5.
PMID:
9440585
DOI:
10.1378/chest.113.1.165
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center